<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2026-12-18-23</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-5121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Оценка активности ревматоидного артрита и проводимой терапии базисными противовоспалительными препаратами у амбулаторных пациентов в реальной клинической практике</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of rheumatoid arthritis activity and treatment with disease-modifying anti-rheumatic drugs in outpatients in routine clinical practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-1087-5087</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Русланова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ruslanova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Русланова Надежда Михайловна, аспирант кафедры пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>Ruslanova Nadezhda M., postgraduate student at Dept of Propaedeutics of Internal Medicine</p></bio><email xlink:type="simple">nadya.ruslanova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4010-1888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евстигнеева</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Evstigneeva</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евстигнеева Людмила Петровна, д. м. н., доцент кафедры поликлинической терапии; зав. отделением ревматологии, главный внештатный ревматолог Минздрава Свердловской области.</p></bio><bio xml:lang="en"><p>Evstigneeva Lyudmila P., Dr Med Sci (habil.), associate professor at Dept of Outpatient Therapy; head of Dept of the Rheumatology, сhief external rheumatologist of the Ministry of Health of the Sverdlovsk Region.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России; ГАУЗ СО «Свердловская областная клиническая больница № 1»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University; Sverdlovsk Regional Clinical Hospital № 1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2026</year></pub-date><volume>0</volume><issue>12</issue><issue-title>Ревматология в общей врачебной практике (1)</issue-title><fpage>18</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Русланова Н.М., Евстигнеева Л.П., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Русланова Н.М., Евстигнеева Л.П.</copyright-holder><copyright-holder xml:lang="en">Ruslanova N.M., Evstigneeva L.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/5121">https://www.med-alphabet.com/jour/article/view/5121</self-uri><abstract><p>Цель: оценить активность ревматоидного артрита (РА) и адекватность проводимой базисной противовоспалительной терапии у амбулаторных пациентов в реальной клинической практике. Материалы и методы. Обследованы 115 пациентов с РА, обратившихся к ревматологу амбулаторно. Активность определяли по индексу DAS 28-СРП; дополнительно учитывали мнение врача об активности, соотношение болезненных и припухших суставов, результаты опросников HADS и FIRST. Проанализирована эффективность регулярного наблюдения. Результаты. По DAS 28-СРП ремиссия/низкая активность выявлены у 43,7 %, умеренная – у 42,7 %, высокая – у 13,6 % пациентов. Вместе с тем объективные признаки воспалительной активности (повышение СРП и ≥1 припухший сустав) отмечены лишь у 22,3 %. У 34,0 % пациентов отмечена завышенная оценка активности по DAS 28, ассоциированная с тревогой, депрессией или фибромиалгией. Признаки хотя бы одного коморбидного из перечисленных состояний выявлены у 52,6 % обследованных. Показана эффективность регулярного наблюдения: высокая активность РА наблюдалась у 32,1 % пациентов с нерегулярными посещениями ревматолога, в то время как при визитах к ревматологу каждые 6 месяцев и чаще активность РА зарегистрирована у 12,0 % пациентов, p=0,014. Неисчерпанный потенциал базисной терапии имели 18,4 % пациентов. Выводы. Индекс DAS 28-СРП может завышать активность РА за счет субъективных факторов, в связи с чем целесообразно проведение скрининга тревоги, депрессии и фибромиалгии. Контроль активности РА улучшается при регулярном наблюдении пациентов, что свидетельствует о необходимости организации диспансерного наблюдения.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To assess rheumatoid arthritis (RA) activity and the adequacy of ongoing conventional disease-modifying anti-rheumatic therapy in outpatients in real-world clinical practice. Materials and methods. A total of 115 outpatients with RA who consulted a rheumatologist were examined. Disease activity was assessed using the DAS 28-CRP index; the physician’s global assessment of activity, the ratio of tender to swollen joints, and the results of the HADS and FIRST questionnaires were also taken into account. The effectiveness of regular follow-up was analyzed. Results. According to DAS 28-CRP, remission/low disease activity was identified in 43.7 % of patients, moderate activity in 42.7 %, and high activity in 13.6 %. At the same time, objective signs of inflammatory activity (elevated CRP and ≥1 swollen joint) were observed in only 22.3 % of patients. In 34.0 % of patients, DAS 28 overestimated disease activity; this was associated with anxiety, depression, or fibromyalgia. Signs of at least one of these comorbid conditions were detected in 52.6 % of the patients examined. The effectiveness of regular follow-up was demonstrated: high RA activity was observed in 32.1 % of patients with irregular rheumatology visits, whereas among patients seen by a rheumatologist every 6 months or more frequently, high RA activity was recorded in 12.0 % (p=0.014). In 18.4 % of patients, the potential of basic therapy had not been fully exhausted. Conclusions. The DAS 28-CRP index may overestimate RA activity due to subjective factors; therefore, screening for anxiety, depression, and fibromyalgia appears advisable. Control of RA activity improves with regular patient follow-up, indicating the need to establish structured dispensary monitoring.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>активность</kwd><kwd>депрессия</kwd><kwd>тревога</kwd><kwd>фибромиалгия</kwd><kwd>диспансерное наблюдение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>activity</kwd><kwd>depression</kwd><kwd>anxiety</kwd><kwd>fibromyalgia</kwd><kwd>regular medical follow-up</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ревматоидный артрит. Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2024. 120 с. URL: https://cr.minzdrav.gov.ru/view-cr/250_3 (дата обращения: 15.01.2026).</mixed-citation><mixed-citation xml:lang="en">Rheumatoid arthritis. Clinical guidelines. Ministry of Health of the Russian Federation, 2024. 120 p. (In Russ.). URL: https://cr.minzdrav.gov.ru/preview-cr/536_3 (access date: 15.01.2026).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen J., Landewé R., Bergstra S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan; 82 (1): 3–18. URL: https://pubmed.ncbi.nlm.nih.gov/36357155</mixed-citation><mixed-citation xml:lang="en">Smolen J., Landewé R., Bergstra S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan; 82 (1): 3–18. URL: https://pubmed.ncbi.nlm.nih.gov/36357155</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">England B., Tiong B., Bergman M. et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res (Hoboken). 2019 Dec; 71 (12): 1540–1555. URL: https://pubmed.ncbi.nlm.nih.gov/31709779</mixed-citation><mixed-citation xml:lang="en">England B., Tiong B., Bergman M. et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res (Hoboken). 2019 Dec; 71 (12): 1540–1555. URL: https://pubmed.ncbi.nlm.nih.gov/31709779</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лила А. М., Олюнин Ю. А., Гордеев А. В. Оценка статуса больных ревматоидным артритом: современные тенденции. Современная ревматология. 2020; 14 (2): 7–13. URL: https://cyberleninka.ru/article/n/otsenka-statusa-bolnyh-revmatoidnym-artritom-sovremennye-tendentsii/viewer</mixed-citation><mixed-citation xml:lang="en">Lila A. M., Olyunin Yu.A., Gordeev A. V. Assessment of the status of patients with rheumatoid arthritis: current trends. Modern Rheumatology Journal. 2020; 14 (2): 7–13. (In Russ.). URL: https://cyberleninka.ru/article/n/otsenka-statusa-bolnyh-revmatoidnym-artritom-sovremennye-tendentsii/viewer</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pincus T., Schmukler J., Block J. et al. Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity? ACR Open Rheumatol. 2023 Jan; 5 (1): 49–50. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9837390</mixed-citation><mixed-citation xml:lang="en">Pincus T., Schmukler J., Block J. et al. Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity? ACR Open Rheumatol. 2023 Jan; 5 (1): 49–50. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9837390</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Desthieux C., Hermet A., Granger B. Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review with Meta-Analysis. Arthritis Care Res (Hoboken). 2016 Dec; 68 (12): 1767–1773. URL: https://pubmed.ncbi.nlm.nih.gov/27059693</mixed-citation><mixed-citation xml:lang="en">Desthieux C., Hermet A., Granger B. Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review with Meta-Analysis. Arthritis Care Res (Hoboken). 2016 Dec; 68 (12): 1767–1773. URL: https://pubmed.ncbi.nlm.nih.gov/27059693</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nikiphorou E., Radner H., Chatzidionysiou K. et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016 Oct 28; 18 (1): 251. URL: https://pubmed.ncbi.nlm.nih.gov/27793211</mixed-citation><mixed-citation xml:lang="en">Nikiphorou E., Radner H., Chatzidionysiou K. et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016 Oct 28; 18 (1): 251. URL: https://pubmed.ncbi.nlm.nih.gov/27793211</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Фоломеева О. М., Насонов Е. Л., Андрианова И. А. и др. Ревматоидный артрит в ревматологической практике России: тяжесть заболевания в российской популяции больных. Одномоментное (поперечное) эпидемиологическое ис следование (RAISER). Научно-практическая ревматология. 2010; 1: 50–60. URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-revmatologicheskoy-praktike-rossii-tyazhest-zabolevaniya-v-rossiyskoy-populyatsii-bolnyh-odnomomentnoe</mixed-citation><mixed-citation xml:lang="en">Folomeeva O. M., Nasonov E. L., Andrianova I. A. et al. Rheumatoid arthritis in rheumatological practice in Russia: disease severity in the Russian patient population. A cross-sectional epidemiological study (RAISER). Scientific and Practical Rheumatology. 2010; 1: 50–60. (In Russ.). URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-revmatologicheskoy-praktike-rossii-tyazhest-zabolevaniya-v-rossiyskoy-populyatsii-bolnyh-odnomomentnoe</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Амирджанова В. Н., Полищук Е. Ю., Аношенкова О. Н. и др. Эффективность и безопасность быстрой эскалации дозы метотрексата при ревматоидном ар трите (результаты многоцентрового исследования «МЕТЕОР»). Научно-практическая ревматология. 2025; 63 (1): 55–64. URL: https://cyberleninka.ru/article/n/effektivnost-i-bezopasnost-bystroy-eskalatsii-dozy-metotreksata-pri-revmatoidnom-artrite-rezultaty-mnogotsentrovogo-issledovaniya</mixed-citation><mixed-citation xml:lang="en">Amirdzhanova V. N., Polishchuk E. Yu., Anoshenkova O. N., et al. Efficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis (results of the multicenter study «METEOR»). Scientific and Practical Rheumatology. 2025; 63 (1): 55–64. (In Russ.). URL: https://cyberleninka.ru/article/n/effektivnost-i-bezopasnost-bystroy-eskalatsii-dozy-metotreksata-pri-revmatoidnom-artrite-rezultaty-mnogotsentrovogo-issledovaniya</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л., Каратеев Д. Е., Сатыбалдыев А. М. и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2015; 53 (5): 472–484. URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-rossiyskoy-federatsii-po-dannym-rossiyskogo-registra-bolnyh-artritom-soobschenie-i</mixed-citation><mixed-citation xml:lang="en">Nasonov E. L., Karateev D. E., Satybaldyev A. M. et al. Rheumatoid arthritis in the Russian Federation according to the Russian Arthritis Registry (Report I). Scientific and Practical Rheumatology. 2015; 53 (5): 472–484. (In Russ.). URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-rossiyskoy-federatsii-po-dannym-rossiyskogo-registra-bolnyh-artritom-soobschenie-i</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Амирджанова В. Н., Погожева Е. Ю., Каратеев А. Е. и др. Ревматоидный артрит в реальной клинической практике: инициация терапии генно-инженерными биологическими препаратами. Результаты проекта «Компьютерные терминалы самооценки для пациентов с ревматическими заболеваниями» («ТЕРМИНАЛ II»). Современная ревматология. 2019; 13. (3): 30–38. URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-realnoy-klinicheskoy-praktike-initsiatsiya-terapii-genno-inzhenernymi-biologicheskimi-preparatami-rezultaty</mixed-citation><mixed-citation xml:lang="en">Amirdzhanova V. N., Pogozheva E. Yu., Karateev A. E. et al. Rheumatoid arthritis in real clinical practice: initiation of therapy with genetically engineered biological drugs. Results of the project «Computer terminals for self-assessment of patients with rheumatic diseases» («TERMINAL–II»). Modern Rheumatology. 2019; 13. (3): 30–38. (In Russ.). URL: https://cyberleninka.ru/article/n/revmatoidnyy-artrit-v-realnoy-klinicheskoy-praktike-initsiatsiya-terapii-genno-inzhenernymi-biologicheskimi-preparatami-rezultaty</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Бобкова А. О., Лила А. М., Каратеев А. Е. Предикторы неэффективности терапии у пациентов с ревматоидным артритом, нуждающихся в смене ГИБП/иJAK: данные одноцентрового проспективного исследования. Терапевтический архив. 2025; 97 (12): 973–980. URL: https://journals.eco-vector.com/0040–3660/article/view/643411</mixed-citation><mixed-citation xml:lang="en">Bobkova A. O., Lila A. M., Karateev A. E. Predictors of ineffective therapy in patients with rheumatoid arthritis requiring bDMARDs/JAKi switching: data from a single-center prospective study. Terapevticheskii arkhiv. 2025; 97 (12): 973–980. (In Russ.). URL: https://journals.eco-vector.com/0040–3660/article/view/643411</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pincus T., Li T., Gibson K. Elevated DAS 28, CDAI, RAPID 3 and five of seven RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQ. Rheumatology (Oxford). 2025 Aug 1; 64 (8): 4555–4564. URL: https://pubmed.ncbi.nlm.nih.gov/40156145</mixed-citation><mixed-citation xml:lang="en">Pincus T., Li T., Gibson K. Elevated DAS 28, CDAI, RAPID 3 and five of seven RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQ. Rheumatology (Oxford). 2025 Aug 1; 64 (8): 4555–4564. URL: https://pubmed.ncbi.nlm.nih.gov/40156145</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Меликова Н. А., Филатова Е. Г., Лила А. М. Фибромиалгия при ревматоидном артрите: особенности болевого синдрома, влияние на активность заболевания и качество жизни пациентов. Современная ревматология. 2022; 16 (1): 32–37. URL: https://cyberleninka.ru/article/n/fibromialgiya-pri-revmatoidnom-artrite-osobennosti-bolevogo-sindroma-vliyanie-na-aktivnost-zabolevaniya-i-kachestvo-zhizni</mixed-citation><mixed-citation xml:lang="en">Melikova N. A., Filatova E. G., Lila A. M. Fibromyalgia in rheumatoid arthritis: characteristics of pain syndrome and its impact on disease activity and quality of life of patients. Modern Rheumatology. 2022; 16 (1): 32–37. (In Russ.). URL: https://cyberleninka.ru/article/n/fibromialgiya-pri-revmatoidnom-artrite-osobennosti-bolevogo-sindroma-vliyanie-na-aktivnost-zabolevaniya-i-kachestvo-zhizni</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Прокофьева Ю. А., Мусаева Л. М., Меньшикова И. В. Роль своевременного контроля эффективности терапии ревматоидного артрита. Consilium Medicum. 2023; 25 (11): 788–792. URL: https://cyberleninka.ru/article/n/rol-svoevremennogo-kontrolya-effektivnosti-terapii-revmatoidnogo-artrita</mixed-citation><mixed-citation xml:lang="en">Prokofieva Yu.A., Musaeva L. M., Menshikova I. V. The role of timely monitoring of rheumatoid arthritis therapy effectiveness. Consilium Medicum. 2023; 25 (11): 788–792. (In Russ.). URL: https://cyberleninka.ru/article/n/rol-svoevremennogo-kontrolya-effektivnosti-terapii-revmatoidnogo-artrita</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Matcham F., Rayner L., Steer S. et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013 Dec; 52 (12): 2136–48. DOI: 10.1093/rheumatology/ket169. Epub 2013 Sep 3. URL: https://pubmed.ncbi.nlm.nih.gov/24003249</mixed-citation><mixed-citation xml:lang="en">Matcham F., Rayner L., Steer S. et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013 Dec; 52 (12): 2136–48. DOI: 10.1093/rheumatology/ket169. Epub 2013 Sep 3. URL: https://pubmed.ncbi.nlm.nih.gov/24003249</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Drakes D., Fawcett E., Yick J. et al. Beyond rheumatoid arthritis: A meta-analysis of the prevalence of anxiety and depressive disorders in rheumatoid arthritis. J Psychiatr Res. 2025 Apr; 184: 424–438. URL: https://pubmed.ncbi.nlm.nih.gov/40112611</mixed-citation><mixed-citation xml:lang="en">Drakes D., Fawcett E., Yick J. et al. Beyond rheumatoid arthritis: A meta-analysis of the prevalence of anxiety and depressive disorders in rheumatoid arthritis. J Psychiatr Res. 2025 Apr; 184: 424–438. URL: https://pubmed.ncbi.nlm.nih.gov/40112611</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Duffield S., Miller N., Zhao S. et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018 Aug 1; 57 (8): 1453–1460. URL: https://pubmed.ncbi.nlm.nih.gov/29788461</mixed-citation><mixed-citation xml:lang="en">Duffield S., Miller N., Zhao S. et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018 Aug 1; 57 (8): 1453–1460. URL: https://pubmed.ncbi.nlm.nih.gov/29788461</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pisaniello H., Whittle S., Lester S. et al. Using the derived 28-joint disease activity score patient-reported components (DAS 28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol. 2022 Nov 15; 6 (1): 67. URL: https://pubmed.ncbi.nlm.nih.gov/36376988</mixed-citation><mixed-citation xml:lang="en">Pisaniello H., Whittle S., Lester S. et al. Using the derived 28-joint disease activity score patient-reported components (DAS 28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol. 2022 Nov 15; 6 (1): 67. URL: https://pubmed.ncbi.nlm.nih.gov/36376988</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Vermeer M., Kuper H., van der Bijl A. et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012 Jun; 51 (6): 1076–80. URL: https://pubmed.ncbi.nlm.nih.gov/22302059</mixed-citation><mixed-citation xml:lang="en">Vermeer M., Kuper H., van der Bijl A. et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012 Jun; 51 (6): 1076–80. URL: https://pubmed.ncbi.nlm.nih.gov/22302059</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Девальд И. В., Ходус Е. А., Игнатова Г. Л. и др. Влияние добавок фолиевой кислоты на эффективность и переносимость разных форм метотрексата у больных ревматоидным артритом. Непрерывное медицинское образование и наука. 2023; 17 (4): 39–51. URL: https://cmedas.elpub.ru/jour/article/view/19</mixed-citation><mixed-citation xml:lang="en">Devald I. V., Khodus E. A., Ignatova G. L. et al. Influence of Folic Acid Supplementation on the Efficacy and Tolerability of Different Forms of Methotrexate in Patients with Rheumatoid Arthritis. Continuous Medical Education and Science. 2023; 17 (4): 39–51. (In Russ.). URL: https://cmedas.elpub.ru/jour/article/view/19</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
